Non-Operating Income/Expense: The sum of all non-operating expenses for the given industry.
Estrella Immunopharma, Inc. (ESLA) Non-Operating Income/Expense data is not available for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-13.06M |
|
-- |
|
-- |
|
$13.06M |
|
$-13.06M |
|
|
Non-Operating Income/Expense |
-- |
$-13.06M |
|
$-13.06M |
|
$-13.06M |
|
$-13.06M |
|
$-13.06M |
|
$-13.06M |
|
$-13.06M |
|
$-13.06M |
|
36.82M |
|
36.82M |
|
$-0.35 |
|
$-0.35 |
|
| Balance Sheet Financials | |
$1.68M |
|
-- |
|
$1.50M |
|
$3.18M |
|
$13.54M |
|
-- |
|
-- |
|
$13.54M |
|
$-10.37M |
|
$-10.37M |
|
$-10.37M |
|
37.97M |
|
| Cash Flow Statement Financials | |
$-1.79M |
|
-- |
|
$2.25M |
|
$0.92M |
|
$1.38M |
|
$0.47M |
|
$0.62M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.12 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.79M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
126.01% |
|
126.01% |
|
-411.14% |
|
126.01% |
|
$-0.27 |
|
$-0.05 |
|
$-0.05 |
|